International Stem Cell Corporation splits its revenue 2 ways in its filings. By operating segments, the largest line in Q2 of fiscal 2026, the quarter ended Jun 30, 2026 was Biomedical Market at $2.5 million, 94% of the total. By sales mix, the largest line in Q2 of fiscal 2026, the quarter ended Jun 30, 2026 was Media at $2.0 million, 73% of the total.
USD in millions. The percent under a figure is the change from the same quarter a year earlier.
| Line |
TTM
Jun 30, 2026
|
Q2 FY2026
Jun 30, 2026
|
Q1 FY2026
Mar 31, 2026
|
Q4 FY2025
Dec 31, 2025
|
Q3 FY2025
Sep 30, 2025
|
Q2 FY2025
Jun 30, 2025
|
Q1 FY2025
Mar 31, 2025
|
Q4 FY2024
Dec 31, 2024
|
Q3 FY2024
Sep 30, 2024
|
|---|---|---|---|---|---|---|---|---|---|
| Revenue |
10
|
3
|
2
|
2
|
2
|
2
|
2
|
2
|
2
|
| Operating segments | |||||||||
| Biomedical Market |
9
+4.1%
share 93.5%
|
3
+9.6%
share 94.4%
|
2
+8.8%
share 93.7%
|
2
-11.0%
share 92.8%
|
2
+10.2%
share 93.0%
|
2
share 94.1%
|
2
share 93.7%
|
2
share 91.9%
|
2
share 91.8%
|
| Anti Aging Skincare Market |
1
-6.1%
share 6.5%
|
0
+4.9%
share 5.6%
|
0
+8.2%
share 6.3%
|
0
-22.1%
share 7.2%
|
0
-7.8%
share 7.0%
|
0
share 5.9%
|
0
share 6.3%
|
0
share 8.1%
|
0
share 8.2%
|
| Sales mix | |||||||||
| Media |
6
+8.4%
share 65.7%
|
2
+26.5%
share 73.1%
|
1
+2.7%
share 57.0%
|
2
+5.8%
share 70.5%
|
1
-2.9%
share 61.5%
|
2
share 63.2%
|
1
share 60.3%
|
1
share 58.7%
|
2
share 68.8%
|
| Cells |
3
-4.7%
share 27.8%
|
1
-25.0%
share 21.2%
|
1
+19.7%
share 36.8%
|
0
-40.7%
share 22.3%
|
1
+49.6%
share 31.6%
|
1
share 30.9%
|
1
share 33.4%
|
1
share 33.1%
|
0
share 22.9%
|
How these figures are calculated
Quarterly columns are single-quarter amounts. When a 10-Q reports only a year-to-date total, as cash flow statements do, the quarter is that total minus the previous quarter's year-to-date total. The fourth quarter is the annual report's full year minus the first nine months. A column marked YTD is a year-to-date total, shown when the earlier report needed for the single quarter is missing. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. The first column adds the latest year-to-date segment amount to the last fiscal year and subtracts the year-ago year-to-date amount. More on our methodology.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- ISCO (OTC)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- San Diego, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1355790
- Former names
- BTHC III INC. (until Jan 19, 2007)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.